TOP TEN perturbations for 39030_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39030_at
Selected probe(set): 203136_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39030_at (203136_at) across 6674 perturbations tested by GENEVESTIGATOR:

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.9422226
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):2.9333973
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):2.8933363
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):-2.568983
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)

Relative Expression (log2-ratio):2.4157267
Number of Samples:6 / 6
Experimental memory B cell study 1 (CD27high)
CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.
Control memory B cell study 1 (undivided)
CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):2.2983513
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.2502527
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.2073717
Number of Samples:3 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

oncolytic herpes simplex virus study 1 / mock infected peripheral nerve sheath tumor (90-8) cell sample

Relative Expression (log2-ratio):-2.1824923
Number of Samples:2 / 2
Experimental oncolytic herpes simplex virus study 1
Human malignant peripheral nerve sheath tumor (90-8) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (90-8) cell sample
Human malignant peripheral nerve sheath tumor (90-8) cells mock infected for 6 hours.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.1735306
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

Organism: Homo sapiens
Gene: 39030_at
Selected probe(set): 203136_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39030_at (203136_at) across 6674 perturbations tested by GENEVESTIGATOR:

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.9422226
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):2.9333973
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):2.8933363
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):-2.568983
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

memory B cell study 1 (CD27high) / memory B cell study 1 (undivided)

Relative Expression (log2-ratio):2.4157267
Number of Samples:6 / 6
Experimental memory B cell study 1 (CD27high)
CD27 enriched proliferating human memory B cells expressing high level of CD27 (marker of antibody secretion) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.
Control memory B cell study 1 (undivided)
CD27 enriched undivided human memory B cells (expressing low level of CD27) activated with CpG oligodeoxynucleotide (10 ng/ml), recombinant human cytokines IL-2 (20 IU/ml), IL-10 (50 ng/ml), IL-15 (10 ng/ml), recombinant human BAFF (75 ng/ml) in PC-L medium (IMDM medium, lacromin (50mg/ml), insulin (5mg/ml), penicillin/streptomycin, gentamicin (15mg/ml), normocin (0.1% v/v), 10% FCS) for 80 hours.

atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)

Relative Expression (log2-ratio):2.2983513
Number of Samples:20 / 19
Experimental atopic dermatitis study 12 (non-lesional; adults)
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control atopic dermatitis study 12 (non-lesional; children)
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.2502527
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.2073717
Number of Samples:3 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

oncolytic herpes simplex virus study 1 / mock infected peripheral nerve sheath tumor (90-8) cell sample

Relative Expression (log2-ratio):-2.1824923
Number of Samples:2 / 2
Experimental oncolytic herpes simplex virus study 1
Human malignant peripheral nerve sheath tumor (90-8) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (90-8) cell sample
Human malignant peripheral nerve sheath tumor (90-8) cells mock infected for 6 hours.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.1735306
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.